Defence Therapeutics Inc.
DTCFF · OTC
6/30/2025 | 6/30/2024 | 6/30/2023 | 6/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.13 | -0.04 | 1.11 | -0.12 |
| FCF Yield | -8.95% | -11.32% | -6.87% | -8.56% |
| EV / EBITDA | -12.23 | -3.26 | -17.18 | 0.00 |
| Quality | ||||
| ROIC | -1,315.83% | 688.65% | -192.67% | 1,882.63% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.97 | 0.33 | 1.13 | 0.82 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 44.40% | 41.84% | -27.78% | -163.99% |
| Safety | ||||
| Net Debt / EBITDA | -0.09 | -0.13 | 0.16 | 0.00 |
| Interest Coverage | -10.14 | 0.00 | -24.65 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -5,062.66 | 0.00 |